within Pharmacolibrary.Drugs.ATC.N;

model N06AX01
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.478,
    Cl             = 0.0004166666666666667,
    adminDuration  = 600,
    adminMass      = 100 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.00041999999999999996,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.00105,
    Tlag           = 600
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>N06AX01</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Oxitriptan (L-5-hydroxytryptophan, 5-HTP) is a naturally occurring amino acid and chemical precursor to serotonin. It has been used as an antidepressant and in the management of conditions related to serotonin deficiency. Oxitriptan is not widely approved as a prescription medication and is more commonly available as a supplement. It is not approved by the FDA for any indication.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters estimated for healthy adult individuals after oral administration.</p><h4>References</h4><ol><li><p>Ebadi, M, Gessert, CF, &amp; Al-Sayegh, A (1982). Drug-pyridoxal phosphate interactions. <i>Quarterly reviews on drug metabolism and drug interactions</i> 4(4) 289–331. DOI:<a href=&quot;https://doi.org/10.1515/dmdi.1982.4.4.289&quot;>10.1515/dmdi.1982.4.4.289</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/6087425/&quot;>https://pubmed.ncbi.nlm.nih.gov/6087425</a></p></li><li><p>Sacchetti, E, Galluzzo, A, &amp; Valsecchi, P (2011). Oral ziprasidone in the treatment of patients with bipolar disorders: a critical review. <i>Expert review of clinical pharmacology</i> 4(2) 163–179. DOI:<a href=&quot;https://doi.org/10.1586/ecp.10.139&quot;>10.1586/ecp.10.139</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/22115400/&quot;>https://pubmed.ncbi.nlm.nih.gov/22115400</a></p></li><li><p>Peterlin, BL, &amp; Rapoport, AM (2007). Clinical pharmacology of the serotonin receptor agonist, zolmitriptan. <i>Expert opinion on drug metabolism &amp; toxicology</i> 3(6) 899–911. DOI:<a href=&quot;https://doi.org/10.1517/17425255.3.6.899&quot;>10.1517/17425255.3.6.899</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/18028032/&quot;>https://pubmed.ncbi.nlm.nih.gov/18028032</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end N06AX01;
